Jade Biosciences
Jade Biosciences is dedicated to developing best-in-class therapies for autoimmune diseases, with a focus on innovative treatments that address critical unmet needs. Its lead candidate, JADE101, targets the anti-APRIL pathway for IgA nephropathy, aiming to reduce harmful IgA antibodies, lower proteinuria, and preserve kidney function. The company is advancing a pipeline that includes additional antibody programs, with plans to initiate clinical trials and present preclinical data, aiming to redefine the standard of care for autoimmune conditions.
Industries
Nr. of Employees
small (1-50)
Products
Anti-APRIL monoclonal antibody candidate for IgA nephropathy (lead candidate)
A fully human monoclonal antibody candidate designed to block the APRIL pathway to reduce pathogenic IgA production, engineered with Fc modifications to extend half-life and support infrequent dosing; advanced through preclinical characterization toward first-in-human studies.
Preclinical antibody development candidate for systemic autoimmune diseases (development candidate)
A development-stage antibody candidate nominated from an antibody discovery program targeting systemic autoimmune indications; currently in preclinical development.
Antibody discovery program (undisclosed preclinical programs)
Undisclosed optimized antibody discovery programs in preclinical stages to generate additional development candidates.
Anti-APRIL monoclonal antibody candidate for IgA nephropathy (lead candidate)
A fully human monoclonal antibody candidate designed to block the APRIL pathway to reduce pathogenic IgA production, engineered with Fc modifications to extend half-life and support infrequent dosing; advanced through preclinical characterization toward first-in-human studies.
Preclinical antibody development candidate for systemic autoimmune diseases (development candidate)
A development-stage antibody candidate nominated from an antibody discovery program targeting systemic autoimmune indications; currently in preclinical development.
Antibody discovery program (undisclosed preclinical programs)
Undisclosed optimized antibody discovery programs in preclinical stages to generate additional development candidates.
Expertise Areas
- Antibody therapeutics development
- Autoimmune disease drug development
- Preclinical development and nonclinical characterization
- Translational medicine and biomarker-driven development
Key Technologies
- Monoclonal antibody therapeutics
- Fc engineering for half-life extension
- Epitope mapping and selective epitope targeting
- High-affinity antibody engineering